Search results for: Lotte Steuten

OHE at ISPOR 2024

5 May 2024, 12:00am

Title Name Date Time Session type Handling Uncertainty in Health Technology Assessment Process Lotte Steuten 05 May 2024 13:00 – 17:00 EDT Short Course A Targeted Literature Review to Identify…

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments

8 January 2021

…of histology independent therapies. This blog summarises the discussion and the audience opinions. First, Lotte Steuten from OHE introduced the nature of problem and specific challenges, based on results of…

Combination Therapies: A Step Forward to the Value Attribution Problem

4 January 2023

…(Ipsen), Dr Lotte Steuten (OHE) and Andrew Bruce (Amgen), explains the ‘not cost-effective at zero price’ paradox: when an ‘add-on’ medicine is used in conjunction with a ‘backbone’ medicine to…

Virtual ISPOR European 2020

10 November 2020

…Assessment of Histology Independent Therapies Lotte Steuten, PhD, MSc Vice President and Head of Consulting, Office of Health Economics Moderator  Lotte will moderate this Educational Symposium where panellists will provide…

Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase

3 October 2019

…team will also comprise Lotte Steuten (specialising in quantitative methods for estimating and comparing the expected health and economic benefits of new approaches and interventions in disease prevention, diagnostics and…

Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology

1 February 2021

…Towse and Lotte Steuten) and Amgen (Mickael Lothgren and Andrew Bruce) contributes to the emerging debate as to why a new approach is required to address the value attribution problem…

The US Inflation Reduction Act: What Do the Experts Think?

25 May 2023

…a session moderated by Prof Lotte Steuten[8], Office of Health Economics, an investor’s perspective was provided by Dr Ravi Mehrotra, 5point0, who estimated that there would be a greater than…

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

10 July 2023

…sequencing over alternatives such as PCR and single gene testing,” said Professor Lotte Steuten, Deputy CEO of OHE and co-author of the report. “This is the cornerstone of the case…

Our team

Our directors Graham Cookson Chief Executive Lotte Steuten Deputy Chief Executive Mireia Jofre-Bonet Chief Research Officer, Head of Education Martina Garau Director Chris Skedgel Director Charlotte Ashton-Khan Director of External…